Correspondence christian-wolfrum@ethz.ch In Brief Lasar et al. show that PPARg is required to maintain the thermogenic capacity of mature brown adipocytes, which can be induced by activating b-adrenergic signaling. They show that expression of the known PPARg target Gyk correlates with human brown fat activity and identify Gyk as a partial mediator of PPARg function.
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INTRODUCTION
Obesity is defined as abnormal fat accumulation and occurs due to a long-term positive energy balance (Mittendorfer, 2011) . The global increase in obesity has been attributed to numerous factors including, but not limited to, altered food consumption as well as a decrease in energy expenditure (Hill et al., 2012) . One possibility to induce energy expenditure is non-shivering thermogenesis in brown adipose tissue (BAT). This process is mediated by Uncoupling protein 1 (UCP1), which differentiates BAT from classical white adipose tissue (WAT). Studies on the regulation of BAT function have led to the identification of key regulatory factors such as peroxisome proliferator-activated receptor g (PPARg), PGC1a, and PRDM16 Petrovic et al., 2010) . Particularly, PPARg2 is an important regulator of both brown and white adipocyte differentiation (Barak et al., 1999; Tontonoz et al., 1994) . Recent evidence derived from the analysis of post-translational modifications of PPARg have implicated this factor not only as a regulator of adipocyte formation, but also as a mediator of brown adipocyte functionality (Choi et al., 2010; Hu et al., 1996; Qiang et al., 2012) . Furthermore, it was reported that Ucp1 mRNA abundance is higher in animals treated with the PPARg agonist rosiglitazone (Festuccia et al., 2010) ; however, whether this is due to a direct induction in mature cells or due to de novo formation of brown adipocytes is unknown. In human multipotent adipose-derived stem (hMADS) cells, rosiglitazone-induced browning leads to increased mitochondrial oxidative capacity, which is maintained independently of rosiglitazone (Loft et al., 2015) . In vivo studies are complicated by the fact that global deletion of PPARg leads to postnatal death at E10 (Barak et al., 1999) . Thus, heterozygous PPARg-deficient mice were shown to be protected from age-induced insulin resistance, while studies using the aP2-Cre to elicit an adipose tissue-specific knockout under obesogenic conditions showed a reduction in weight gain and lipodystrophy (He et al., 2003; Jones et al., 2005) . Interestingly, a murine study using the aP2-CRE-ER T2 driver line to promote a tamoxifen-dependent inducible knockout of PPARg demonstrated a reduction of white and brown adipocyte survival (Imai et al., 2004) ; however, given the drastic metabolic phenotype of these animals, due to ablation of PPARg in white adipocytes, it is unclear to what extent PPARg expression in BAT contributes to the observed phenotype. While it is well accepted that PPARg at least in part mediates mature brown adipocyte functionality, surprisingly little data exist on downstream targets. It has been previously shown that PPARg activates UCP1 expression by binding to the UCP1 peroxisome proliferator response element (PPRE) by nuclear translocation and binding of factors like retinoid X receptor (RXR) and PGC1a (Cao et al., 2004) . Here, we demonstrate that PPARg maintains thermogenic function and the ability of BAT to be activated by b 3 -stimulation. Using transcriptional analysis and loss-and gain-of-function studies, we show that part of the effect of PPARg might be mediated through the PPARg target glycerol kinase (GYK) (Barquissau et al., 2016; Chakrabarty et al., 1983; Guan et al., 2002; Mazzucotelli et al., 2007) .
RESULTS
To analyze the role of PPARg in mature brown adipocytes and to exclude the regulation of adipocyte differentiation, we utilized a reverse transfection approach in fully differentiated, immortalized brown adipocytes (IBAs). We obtained approximately 70% of knockdown for both Pparg1 and Pparg2 on both protein and mRNA abundance ( Figures 1A-1C) , which led to a reduction of brown adipocyte-specific transcripts such as Ucp1 and Cidea as well as Ppara ( Figure 1A) . Similarly, we could show that loss of PPARg expression led to an almost complete loss of UCP1 protein expression (Figures 1B and 1C) . To elucidate whether this effect was due to de-differentiation of the adipocytes, we analyzed gene expression of brown and white mature and precursor markers. As shown in Figure S1A , we observed a varied response; for example, the expression of the preadipocyte marker Pref1 was reduced, suggesting that knockdown of Pparg does not lead to a dedifferentiation of the mature adipocytes. In a mitochondrial stress test, basal respiration of IBAs upon PPARg ablation was not altered; however, loss of PPARg inhibited the ability of IBAs to respond to b-adrenergic stimulation as a result of reduced basal and leak respiration ( Figures 1D and 1E) . A glucose stress test demonstrated that IBAs, upon PPARg ablation, induced glycolysis as well as the glycolytic capacity ( Figures 1F and 1G ). In line with these findings, we could show that induction of UCP1 protein and mRNA expression in response to a b-adrenergic stimulation was lost in IBAs with suppressed PPARg expression ( Figures 1H and S1B ). The effect was independent of global PKA activity ( Figure 1I ) and a more detailed analysis of specific targets revealed that phosphorylated hormone sensitive lipase (pHSL) and HSL were mildly reduced after PPARg ablation ( Figure 1J ). Furthermore, we observed a significant reduction of activated cAMP response element-binding protein (p-CREB) and an inability of cAMP to stimulate Ucp1 mRNA expression in the absence of PPARg (Figures S1C-S1E) . Similarly, we could show, that PPARg ablation led to a reduction in isoproterenol stimulated lipolysis ( Figures  1K and S1F ). Taken together, these findings demonstrate that loss of PPARg in mature brown adipocytes reduces the capacity to initiate the thermogenic program by b-adrenergic stimulation.
Since no functional studies analyzing the role of PPARg in mature brown adipocytes exist, we generated an inducible brown-fat-specific PPARg-deficient mouse model to deplete PPARg exclusively in mature brown adipocytes (PPARg-BATKO). Induced genetic ablation of PPARg led to a reduction in Pparg mRNA expression (Figures 2A), a down-regulation of Ucp1 mRNA and protein expression (Figures 2C and 2B) and of other BAT markers such as Cidea and Cox7a1 ( Figure 2C ) and Ppara. Conversely, we did not observe any reduction of either Pparg or Ucp1 mRNA in iWAT ( Figure S2E ). Phenotypic characterization of PPARg-BATKO mice showed neither a weight phenotype nor any differences in body composition ( Figures 2D and S2A) ; however, we observed increased circulating TAG, cholesterol, glucose, and non-esterified fatty acids (NEFA) levels ( Figures 2E-2G ). PPARg-BATKO animals had reduced BAT wet weight ( Figure 2J ) and histological analysis of interscapular BAT depots revealed smaller adipocytes containing less and/or smaller lipid droplets resulting in a higher cell density ( Figures 2H and 2I ), without any changes in total cell numbers. Last, pHSL, HSL, and the pHSL/HSL ratio were reduced in BAT of PPARg-BATKO mice (Figures 2K and 2L) . Taken together, we could show that loss of PPARg in mature brown adipocytes leads to a reduced systemic substrate utilization, concomitant with a reduction in BAT marker gene expression.
To investigate, whether PPARg ablation in BAT would alter systemic respiration, PPARg-BATKO and littermate controls were cold challenged for 7 days at 8 C. Food and water intake at room temperature was similar ( Figure S3A) , and, while in cold, PPARg-BATKO mice exhibited elevated food and water intake ( Figure S3B ). Even though core body temperature was unaffected after a prolonged cold stimulus in these mice (Figure S2D) , visual examination of the mice suggested an increased shivering response, which together with alterations in food and water intake complicates the quantification of the contribution of PPARg to energy expenditure ( Figures S3C and S3D) . Furthermore, the inability of the PPARg-BATKO mice to induce BAT activity might affect the shivering response (Shefer and Talan, 1998) , which in turn could confound the quantification of energy expenditure. Therefore, we acutely treated PPARg-BATKO with the b 3 -adrenergic receptor agonist CL316,243. Both PPARg-BATKO and wild type mice showed similar rates of VO 2 and VCO 2 at baseline ( Figures 3A and 3B ). Upon CL316,243 injection, PPARg-BATKO failed to induce respiration in the same manner as wild-type (WT) animals ( Figures 3D and 3E ). This reduced response in PPARg-BATKO resulted in a higher RER in PPARg-BATKO ( Figure 3C ). To exclude any compensatory effects, we repeated the experiments at thermoneutrality, which led to similar results ( Figures 3D-3F ). Taken together, those data underline the importance of PPARg in maintaining brown adipocyte functionality in response to b 3 -adrenergic receptor activation.
Based on previous work, we hypothesized that PPARg controls BAT functionality by regulating Ppara expression (Barbera et al., 2001 ). In accordance, we could show that depleting PPARa in mature IBAs by reverse transfection reduced expression of brown adipocyte markers Ucp1 and Cidea both on mRNA and on protein level ( Figures 4A and 4B ). To determine whether PPARa was also responsible for maintaining BAT function in vivo, we ablated PPARa specifically in BAT (PPARa-BATKO). PPARa depletion in BAT did not affect classic BAT marker expression, while bona fide PPARa markers were reduced ( Figures 4C and 4D ). Food and water intake were unaltered at room temperature and during cold exposure ( Figure 4E ) in PPARa-BATKO mice and we did not observe any changes in VO 2 , VCO 2 , or RER ( Figures 4F-4H ). Similar to PPARa, expression of Pparb/d was dispensable for BAT function, in vivo as demonstrated by the generation of PPARb/d-BATKO ( Figures  S4A and S4B ). Based on these data, we conclude that PPARa plays a role in brown adipocyte function in vitro; however, both PPARa and PPARb/d seem to be dispensable for mature brown adipocyte functionality, in vivo.
To elucidate the pathway by which PPARg reduces the capacity of BAT to be activated, we transcriptionally profiled the BAT of 3 days cold-challenged C57BL6/N animals and littermates at room temperature (RT), as well as IBAs in the presence or absence of PPARg. To identify direct brown adipocyte targets of PPARg, we analyzed both the in vivo and in vitro comparison for genes that bear PPRE, based on a published chromatin immunoprecipitation (ChIP)-atlas (Nielsen et al., 2008) . We found 231 regulated genes in PPARg-depleted IBAs and 168 genes in cold-acclimatized mice ( Figure 5A ). An intersection of those two lists resulted in 18 genes that were regulated in vitro and in vivo and are classified as PPAR target genes (Table S1 ). Of these 18 genes, only Fabp3 and Gyk, which has been previously identified as a PPARg target in BAT (Guan et al., 2005) , were enriched in BAT. PPARg knockdown in IBAs led to a significant downregulation of Gyk mRNA and protein expression both in the basal as well as in the isoproterenol-induced state ( Figures 5B, 5C , and S5). In accordance with previous results (Festuccia et al., 2010; Festuccia et al., 2003) , we could show that Gyk expression is elevated both in iBAT and iWAT after cold acclimatization (Table S1 ; Figure 5D ). Additionally, we observed an increased GYK mRNA abundance in brown versus white differentiated hMADs cells ( Figure 5E ). In human deep-neck biopsies, the abundance of GYK correlated with UCP1, demonstrating that GYK is a surrogate for BAT quantity and activity ( Figure 5F ). Furthermore, positron emission tomography/computed tomography (PET/CT)-guided biopsy of human supraclavicular BAT showed higher brown adipocyte marker and GYK gene expression compared to WAT samples ( Figure 5G ). Taken together, these results confirm that GYK is a direct target of PPARg in brown adipocytes and that similar to UCP1 GYK is regulated by cold induction in both mice and humans.
To test whether GYK ablation would result in a similar phenotype as a PPARg knockdown, we performed a small interfering RNA (siRNA)-mediated knockdown of GYK in IBAs, which resulted in an 80% reduction of Gyk mRNA and protein expression (Figures 6A, 6B, and S6C). Interestingly, GYK knockdown led to a reduction of UCP1 protein expression (Figures 6B and S6D) and pHSL levels under basal and stimulated conditions. After GYK knockdown, isoproterenol treatment failed to induce both GYK and UCP1 protein expression (Figures 6C, S6C, and S6D), while we observed a slight induction of PPARg2 but not PPARg1 expression ( Figures 6C, S6A , and S6B). GYK knockdown did change adipocyte differentiation (Figures S6G-S6I), and we were able to show that treatment of IBAs with a competitive inhibitor of GYK (Seltzer et al., 1986) led to a dose-dependent reduction in Ucp1 levels ( Figure 6D ). Rosiglitazone was unable to rescue BAT-specific gene expression in GYK-ablated cells ( Figure 6E ), underscoring the importance of GYK for maintaining mature brown adipocyte functionality. Since GYK ablation in vivo causes lethality at P4 (Rahib et al., 2007) , we analyzed the role of GYK in BAT by local overexpression of Gyk through adenoviral-mediated gene delivery in both WT and PPARg-BATKO mice. Re-expression of GYK did not alter body weight and led to an approximately 2-fold induction of GYK expression in iBAT of both WT and PPARg-BATKO mice (Figures 6E and 6F) , which is similar to the effect of a cold stimulation. Similarly, we observed a 1.6-fold increase in iBAT weight and 2.5-fold increase in total protein mass when GYK expression was induced only in PPARg-BATKO mice (Figures 6G and S6F) . In general, overexpression of GYK by adenovirus was able to restore the total levels of GYK to approximately 50% of the WT control, and we observed a similar increase of about 40% for total UCP1 levels. These data demonstrate that GYK can modulate iBAT activity in vivo and that the effect of PPARg ablation on UCP1 expression is in part mediated through GYK. Similar to the results obtained from PPARg knockdown, the respiration of IBAs upon GYK siRNA-mediated knockdown were not changed (Figures 6H and 6I) ; however, when stimulated by isoproterenol, Gyk siRNA-treated cells showed reduced leak respiration. Interestingly, we observed a slight increase in ATP production in Gyk siRNA-treated cells under basal condition (Figures 6H and 6I) , and a glucose stress test showed that IBAs, upon GYK siRNA knockdown, exhibit an increase in glycolysis (Figures 6J and 6K) . GYK generates glycerol-3-phosphate (G3P) from glycerol (Robinson and Newsholme, 1969) , which is required to form lysophosphatidic acid (LPA) a key intermediate in TAG (C) RER of 4 hr before and after CL316,243 injection of WT and PPARg-BATKO at RT (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD; ***p % 0.005).
(D) AUC analysis of VO 2 at RT of WT and PPARg-BATKO after CL316,243 (CL) injection (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD; *p % 0.05).
(E) AUC analysis of VCO 2 at RT of WT and PPARg-BATKO after CL injection (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD). (F) VO 2 of WT and PPARg-BATKO with CL316,243 injection (1 mg/kg BM, i.p.) at 30 C (n = 6 per group).
(G) VCO 2 of WT and PPARg-BATKO with or without CL316,243 injection (1 mg/kg BM, i.p.) at 30 C (n = 6 per group).
(H) RER of 4 hr before and 4 hr after CL316,243 injection of WT and PPARg-BATKO at 30 C (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD; ***p % 0.005).
(I) AUC analysis of VO 2 4 hr after CL316,243 injection of WT and PPARg-BATKO (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD; *p % 0.05).
(J) AUC analysis of VCO 2 4 hr after CL316,243 injection of WT and PPARg-BATKO (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD; *p % 0.05). (legend continued on next page) synthesis. As expected, both GYK and PPARg knockdown led to a reduction of G3P in IBAs ( Figure 6L ) and GYK knockdown led to a reduction of LPA and DAG levels ( Figure 6M ). Interestingly, fatty acid CoA levels were higher in GYK-ablated cells, suggesting that loss of PPARg and GYK leads to a reduced capacity for TAG formation. To identify deregulated pathways, we performed microarray analyses on IBAs with GYK ablation. We could identify 124 downregulated and 142 upregulated genes (Tables S4 and S5 ). Since several of these genes are involved in the regulation of metabolism we performed a transcription factor (TF) enrichment analysis, using the Metacore platform. As shown in Figure 6N the top predicted TFs that could explain the observed regulation were PPARa and PPARg, suggesting a feedback loop for transcriptional regulation. In conclusion, our data identify the PPARg/GYK axis as an important node for the maintenance of mature brown function, which is required for inducibility and the capacity to oxidize lipids in response to brown adipocyte activation.
DISCUSSION
Our results show that PPARg is necessary to maintain BAT thermogenesis and especially its inducibility by acute thiazolidinediones (TZD), cAMP, or b-adrenergic stimuli in mature brown adipocytes, in vitro and in vivo. We did not observe any changes in PPARg and Ucp1 expression in the iWAT depot, which could be due to the timing of the tamoxifen treatment. Since it has been recently shown that the main Ucp1-dependent thermogenic capacity in mice is located in classical BAT we focused our subsequent studies on this particular tissue (Kalinovich et al., 2017) . Even though PPARa has an effect on brown adipocyte function in vitro (Barbera et al., 2001) Research data from pharmacological studies have identified PPARg as an important regulator of BAT function. Thus, it is possible to switch in an hMADs cell-culture system the phenotype of a ''white like'' adipocyte to an activated brown adipocyte even though these cells do not respond to b-adrenergic stimulation. Interestingly, we have recently shown that hMADs cells before rosiglitazone treatment have a protein signature similar to that of a brown adipocyte in the non-activated states (M€ uller et al., 2016) . Therefore, it is possible that pharmacological induction of PPARg can cause the activation of these cells, although the mechanism is not yet known.
It has been shown that noradrenalin treatment leads to the acute downregulation of PPARg expression and that its expression is restored after 24 hr, which is in line with our findings presented here (Lindgren et al., 2004) . Furthermore, it was reported that mice treated with TZDs induce the amount of BATs, without inducing beta-oxidation. This could be due to negligible effects of brown fat induction, which is unlikely given the strong reported effects of BAT ablation and Ucp1 knock out on the systemic metabolism (Feldmann et al., 2009) . A second option is that TZDs promote lipogenesis and dampen the b-adrenergic-mediated activation of adipocytes in vivo, thus masking BAT activation through other systemic alterations. Last, based on the data reported here, it is possible that activation of PPARg primes the brown adipocytes for induction. This is in line with observations that TZD pre-treatment in cells significantly enhances the inducibility by stimuli such as b-adrenergic activation (Hernandez et al., 2003 (Hernandez et al., , 2004 .
From the results presented here, we propose that GYK is at least in part required for mediating PPARg function in BAT and thus constitutes a molecular link for maintenance of inducible brown adipocyte thermogenesis. This is in line with previous reports demonstrating that GYK is a direct PPARg target in brown adipocytes (Guan et al., 2005) . Next to UCP1, several marker genes for brown adipocytes have been reported (Jespersen et al., 2013; Sharp et al., 2012; Ussar et al., 2014) . While GYK is not a unique marker for brown tissue our data clearly indicate that GYK is highly correlated with the amount of functional BAT in humans, suggesting that it is required for brown adipocyte thermogenic function. This is supported by the tissue-specific expression of GYK in BAT and liver (Rahib et al., 2007; Robinson and Newsholme, 1967) and the strong induction in WAT over BAT expression coupled to the findings that showed that GYK induction by thiazolidinedione stimulates glycerol incorporation into triglycerides and reduces free fatty acid secretion from adipocytes (Guan et al., 2002) .
Based on our data, loss of PPARg leads to a reduced expression of GYK, thereby reducing the availability of the substrate G3P for esterification of fatty acids, which leads to reduced TAG synthesis and lipid storage. This in turn might lead to a reduced capacity to sustain brown adipocyte function since lipolysis is the main driver of thermogenesis (Haemmerle et al., 2006) and in turn regulates PPARg activity in BAT. Based on our data, it is furthermore possible that GYK similar to ATGL (Haemmerle et al., 2011 ) is necessary to maintain the activity of PPARs, which is supported by our observation that the expression of PPARa and PPARg target genes is reduced in the absence of GYK. Given our data on the role of PPARa in mature brown function, it is plausible that this effect is mainly due to the regulation of PPARg. Even though multiple different lipids have been suggested as PPARg ligands it is unlikely that the effect, we observe is ligand dependent, as we were not able to rescue GYK ablation through the addition of rosiglitazone. As it is well established that PPARg activation is highly dependent on posttranscriptional modifications (Ahmadian et al., 2013) , it is possible that GYK knockdown might activate a pathway, which cause a repression of PPARg activity, by a so-far unknown post-transcriptional mechanism, independent of ligand-mediated activation.
By overexpressing GYK in interscapular BAT, we could induce thermogenic capacity, similar to an acute cold exposure. Taken together with recent reports demonstrating an induction of (E) Relative mRNA abundance of Ucp1 and Gyk of hMADS differentiated into white and brown adipocytes (n = 6 white versus 6 brown; data are expressed as mean ± SD; *p % 0.05).
(F) Correlation of relative mRNA abundance of UCP1 and GYK in human deep-neck samples (n = 7). (G) Relative mRNA abundance of UCP1, CIDEA, COX7A1, and GYK in PET-CT guided human brown and white adipose tissue of the supraclavicular area (n = 7 white versus 7 brown; data are expressed as mean ± SD; ***p % 0.005). mRNA data are normalized to 36B4. Gyk expression upon cold stimulation (Festuccia et al., 2010; Festuccia et al., 2003) , it is likely that GYK mediates cold-induced brown functionality in response to such a stimulus. In this context, our data establish a link between cold induction and PPARg activation that both induce brown fat functionality. Since TZDmediated induction of BAT mass and function and b3-receptor activation of thermogenesis are two major regulatory nodes of BAT, our data identify GYK as the link between these two pathways and thus serve as a target for inducing thermogenesis.
EXPERIMENTAL PROCEDURES
Mice C57BL/6N WT mice for experiments and breeding of transgenic lines were obtained from Charles River Laboratories. The mouse strain containing a floxed locus of PPARg (PPARgfl/fl) was created in the labs of Pierre Chambon (Imai et al., 2004) . PPARa and PPARb/d animals were provided by W.W. All animals were kept on an inverted 12-hr-light cycle (beginning of dark phase at 7.00 a.m.), fed ad libitum chow diet. Animals were kept at 23 C housing temperature when not under cold stimulation. For tissue sampling, animals were euthanized singly in a carbon dioxide atmosphere. Unless stated otherwise, all experiments were performed with adult (11-14 weeks) male mice. Animals used in the study all carried the UCP-ERCre allele (Rosenwald et al., 2013) and the floxed PPAR allele as indicated. Tamoxifen induction of Cre activity was performed as well in WT and knockout (KO) animals by gavaging the mice 4 times with 10 mg/mL per g body mass tamoxifen (Sigma) in sunflower oil (Denner) when kept at 8 C for 6 days. Experiments and further analysis were performed 7 days after cold induction. All animal procedures were approved by national and institutional guidelines.
Calorimetric Measurements
For measurements of respiratory quotient (respiratory exchange ratio, RER), locomotor activity, food and water intake, a metabolic cage system was used (Phenomaster, TSE Systems). Standard settings according to the manufacturer's instructions were used. Mice were fed ad libitum chow diet and water and consumption was determined during a full 24-hr-light cycle after the animals could acclimatize to the cage and/or temperature for 24 hr. Parameters were calculated to individual lean mass that were determined by echo MRI. To generate b 3 -adrenergic stimulation, mice were intraperitoneally (i.p.) injected with CL316,243 1 mg/kg BM.
Blood Parameters
Whole blood was sampled and adjusted to approximately 5 mM EDTA. Samples were incubated for 10 min at RT and centrifuged 5 min 300 3 g.
Supernatant was flash-frozen in liquid nitrogen. Free fatty acid concentration was determined with the NEFA-HR kit (Wako). To estimate triacylglycerol and cholesterol concentration, Trig/GB and Chol kits (both Roche) were. Blood glucose levels were determined using Contour glucometers (Bayer).
Glucose Uptake
In IBAs, glucose uptake was performed on the second day after reverse transfection with either non-targeting (NT) siRNA or Pparg siRNA. Cells were incubated at 37 C in Krebs Ringer buffer containing insulin, 2 mM glucose, and C-deoxyglucose (200 cpm/mL). After 2 hr, cells were washed twice with ice-cold PBS and lysed by one freeze thaw cycle in 2 M NaOH. Lysates were mixed with 3 mL scintillation cocktail and intracellular radioactivity was quantified in disintegrations per minute (dpm).
Paraffin Sections
Adipose tissues were excised, placed in embedding cassettes, and stored in cold PBS. Samples were fixated in 4% paraformaldehyde (Sigma) in PBS (Gibco) at RT. Processing was performed according to the standard protocol in a STP 120 (Microm), and samples were embedded in paraffin and cut into 5-mm-thin sections on a Hyrax M55 (Zeiss). Sections were de-paraffinized and stained with H&E on a Varistain 24-4 (Shandon) before mounting and drying. Images were obtained with an Axioscope A.1 (Zeiss).
Cell Lines
Immortalized preadipocyte cell lines derived from the stromal-vascular fraction of either interscapular BAT tissue of newborn or young mice were established and provided by Dr. N. Perwitz and Prof. J. Klein (Universitä t L€ ubeck) according to standard protocols (Klein et al., 2002; Perwitz et al., 2010) . Cells were cultured in high glucose (5 mM) DMEM containing 20% fetal calf serum (FCS). All lines were maintained below confluency. To induce adipogenic differentiation, the cell lines were grown to confluence on collagen-coated tissue culture plates and maintained for 2 additional days. Immortalized brown preadipocytes were induced by stimulation with 115 mg/mL IBMX, 1 mM dexamethasone, 20 nM insulin, 125 mM indomethacin, and 1 nM T 3 in full medium. After 24 hr, the medium was exchanged for full medium plus 20 nM insulin and 1 nM T 3 . Cells were maintained in this medium until sampling for analysis. To stimulate UCP1 expression for final read-out, the cells were incubated in full medium with 1 mM isoproterenol for 8 hr before fixation or lysis. For siRNA-mediated knockdown, Dharmacon smartPOOL on-target PLUS RNA pools were used for reverse transfection. 25 nmol of siRNA were incubated for 20 min in 0.25% Lipofectamine RNAiMAX in OptiMEM. Subsequently, they were mixed with cells in full growth medium and plated on collagen-coated plates. siRNA-containing medium was replaced by full growth medium 24 hr after lipofection. The sequences of the used siRNAs are listed in Table S3 . Metacore TF enrichment analysis of siGyk knockdown in IBA versus siNT controls (p values are annotated; bars depict the inverted p value log to 10).
hMADS Cell Culture
The establishment and characterization of hMADS cells have been previously described (Rodriguez et al., 2004) . Cells were used between passages 14 and 25. Cells were seeded at a density of 5,000 cells/cm 2 in DMEM supplemented with 10% FBS, 15 mM HEPES, 2.5 ng/mL hFGF2, 60 mg/mL penicillin, and 50 mg/mL streptomycin. hFGF2 was removed when cells reached confluence. Cells were induced to differentiate at day 2 post-confluence (designated as day 0) in DMEM/Ham's F12 media supplemented with 10 mg/mL transferrin, 10 nM insulin, 0.2 nM triiodothyronine, 1 mm dexamethasone, and 500 mm isobutyl-methylxanthine (IBMX). Two days later, the medium was changed (dexamethasone and IBMX omitted) and 100 nM rosiglitazone was added. At day 9, rosiglitazone was withdrawn to enable white adipocyte differentiation but again included between days 14 and 18 to promote white to brite adipocyte conversion as we previously described (Pisani et al., 2014) . Media were changed every other day and cells were used for analyses at day 18.
White BAT Biopsies from Patients
The clinical study for deep-neck biopsy was approved by the Local Ethics Committee at the University Hospital in Bratislava, Slovakia, and it conforms to the ethical guidelines of the 2000 Helsinki declaration. All study participants provided witnessed written informed consent prior entering the study. Deepneck and adjacent subcutaneous adipose tissue samples were obtained from the lower third of the neck by an experienced ear, nose, and throat (ENT) surgeon from seven middle-aged (38.7 ± 3.1 years) non-obese (BMI 23.7 ± 0.4 kg/m 2 ; waist circumference 82.1 ± 3.0 cm; body fat 28.7% ± 1.3 %) individuals (1M/6F) during neck surgery under general anesthesia (i.e., thyroid surgery [n = 6] or branchial cleft cyst surgery [n = 1]). The deep-neck adipose tissue sample was taken from pre-and paravertebral space between common carotid and trachea in case of thyroid surgery and just laterally to carotid sheath in case of branchial cleft cyst surgery. In all cases, surgical approach was sufficient to reach and sample the deep-neck adipose tissue without any additional morbidity. Patients with malignant disease and subjects younger than 18 years were excluded from participation in the study. The PET/CT-guided human supraclavicular WAT and BAT samples were taken as previously described (Orava et al., 2011) .
Cellular Respiration
Differentiated cells were reverse transfected on rat collagen-coated 96-well Seahorse cell-culture microplates. The oxygen consumption rate (OCR) measurements were performed at 37 C using an XF96 extracellular flux analyzer (Seahorse Bioscience).
RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR Total RNA was extracted from tissues or unsorted cells using Trizol reagent (Invitrogen). Final RNA samples were re-precipitated with NaOAc and ethanol and washed with 70% ethanol before analysis on a Nanodrop-2000 spectrophotometer. RNA from the human supraclavicular WAT and BAT samples was isolated as previously described (Orava et al., 2011) . Reverse transcription was performed using the High Capacity cDNA Reverse transcription kit (Applied Biosystems) with 20-2,000 ng of RNA for cell preparations or whole-tissue preparations. qPCR was performed on a StepOnePlus (Applied Biosystems), and relative mRNA concentrations normalized to the expression of 36B4 were calculated by the DDCt method. qPCR primers and TaqMan probes are listed in Table S2 .
Microarrays
For microarray analyses, RNA preparations were checked for RNA integrity and purity on Bioanalyser RNA nano chips. In case of adipocyte or SVF preparations, 600 ng of total RNA per sample was labeled with the Microarray Quick Amp Labelling Kit (Agilent) according to the manufacturer's instructions. RNA samples of whole adipose tissue were labeled as a service provided by the Functional Genomics Centre Zurich (FGCZ). Hybridization to 4 3 44k whole-mouse microarrays (Agilent) measurements and processing of raw data were provided by the FGCZ. TF enrichment analysis was performed using the Metacore platform.
Western Blotting
Protein amounts were assessed using the DC Protein Assay (Bio-Rad). Western blotting was carried out following standard procedures and chemiluminescence signals were detected by an LAS 4000 mini ImageQuant system (GE Healthcare). Primary antibodies used were as follows: UCP1 (1:1,000; ab10983 Abcam), HSL (1:1,000; #4107 Cell Signaling Technology), p-HSL (Ser660, 1:1,000; #4126 Cell Signal), GAPDH (D16H11, 1:1,000; #5174 Cell Signal), g-tubulin (1:1,000; T6557 Sigma), p-CREB (S133, 1:1000; #9198 Cell Signal), CREB (1:1,000; #9197 Cell Signal), S6 ribosomal Protein (1:1,000; #2217 Cell Signal), p-S6 ribosomal Protein (1:1,000; #5364 Cell Signal), PPARg (1:1,000; #2443 Cell Signal), GYK (1:1,000; ab126599 Abcam), and HSP90 (1:1,000; #4877 Cell Signal).
Metabolomics
IBAs were reverse transected in a 6-well plate with approximately 5 3 105 cells/well. Cells were left to attach for approximately 24 hr, followed by complete medium removal, and washed with 1 3 PBS. Fresh medium was added, and cells were incubated for further 24 hr. Sampling for metabolomics experiment was performed as follows: the medium was removed, and cells were washed twice with cold PBS and quenched by snap freezing the plate in liquid N2.
Plates were stored at -80 C until proceeding with metabolite extraction.
The cold (-20 C) extraction solution (acetonitrile/methanol/water [2:2:1]) was used for metabolite extraction. 400 mL of cold extraction solution was added to each well and incubated for 10 min at -20 C. The supernatant was transferred to a tube and stored on ice. Then, the extraction was repeated by adding additionally 400 mL of cold extraction solution followed by an incubation at -20 C. By keeping the plates on ice, cells were scraped and transferred to the same tube used for the first extraction. Extracts were centrifuged (4 C, 13,000 rpm for 2 min), and the supernatants were transferred to fresh tubes. Clean extracts were used for untargeted metabolomics, while supernatants were evaporated to complete dryness for targeted measurements. For targeted metabolomics, the dried samples were resuspended in 100 mL deionized water, and 15-mL aliquots were injected into a Waters Acquity UPLC (Waters Corporation, Milford, MA) with a Waters Acquity T3 column coupled to a Thermo TSQ Quantum Ultra triple quadrupole instrument (Thermo Fisher Scientific) with negative-mode electrospray ionization. Compounds were separated by a gradient of two mobile phases (A) 10 mM tributylamine, 15 mM acetic acid and 5% (v/v) methanol, and (B) 2-propanol. Acquisition of mass isotopomer distributions of intact and fragmented carbon backbones was done as previously described (R€ uhl et al., 2012) .
Statistical Analysis
Unless stated otherwise, data are presented as mean ± SD. Unpaired and paired two-sided Student's t tests were used for comparisons with *p < 0.05, **p < 0.01, and ***p < 0.005 compared with control group. p > 0.05 are marked as not significant or depicted with their exact p value. Area under the curve (AUC) was calculated using the trapezoid method. Metabolomics data were analyzed by using MATLAB R2015b and software developed in house. Student's t test distribution was used for calculating the significant changing metabolites between different groups. Storey's multiple testing correction was used for p values to account for false discovery rate (Storey and Tibshirani, 2003) .
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data in this study is NCBI GEO: GSE103474.
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